diseases in general practice 5) . Therefore, according to these guidelines, it is important to encourage the training of specialists of FH in each country and educate general practitioners regarding the diagnosis and treatment of FH. We hope that these guidelines will help to spread knowledge regarding the clinical implications of FH throughout the Asia-Pacific region and identify gaps in care, including collaborative efforts to enhance detection (especially in children), the introduction of effective early treatment, the development of country-specific models of care and the establishment of family support groups, relevant research agendas and funding mechanisms by the government and other organizations.
Impact of the Integrated Guidance on the Care of Familial Hypercholesterolaemia
diseases in general practice 5) . Therefore, according to these guidelines, it is important to encourage the training of specialists of FH in each country and educate general practitioners regarding the diagnosis and treatment of FH. We hope that these guidelines will help to spread knowledge regarding the clinical implications of FH throughout the Asia-Pacific region and identify gaps in care, including collaborative efforts to enhance detection (especially in children), the introduction of effective early treatment, the development of country-specific models of care and the establishment of family support groups, relevant research agendas and funding mechanisms by the government and other organizations. . On behalf of the Asia-Pacific Society of Atherosclerosis and Vascular Biology (APSAVD), we herein describe our perspective regarding the care of FH. In this summary, the authors described the guidelines for the detection, diagnosis, assessment and management of familial hypercholesterolemia (FH) in adults and children, which were determined following the discussions held at seminars and workshops at the 16th International Symposium on Atherosclerosis in Sydney in 2012. The recommended treatment is based on risk stratification, the management of non-cholesterol risk factors and the administration of safe and effective treatment to lower the LDL-cholesterol level. In addition to treatment with lipid-lowering medications, such as statins, ezetimibe, resin, fibrates and probucol, the authors described emerging therapies for FH, including mipomersen, lomitapide and anti-PCSK9 antibodies. These guidelines should have a significant impact on the management of FH in the Asia-Pacific region, as awareness of the clinical importance of FH remains very low in many countries, despite the fact that more than half of the world's population lives in this region. In the Asia-Pacific region, Japan and Australia are the only countries with published guidelines in English for the diagnosis and management of FH 2, 3) , and only a few countries have published such guidelines in their mother language. FH is an autosomal dominant disease caused by the presence of abnormal LDL receptors or LDL receptor-related genes that is characterized by the triad of hyper-LDL-cholesterolemia, premature coronary artery disease (CAD) and tendon/cutaneous xanthoma. In our Japanese guidelines, we revised our diagnostic criteria for heterozygous FH, as indicated in Table 1 , in a somewhat similar fashion to Simon Broome's criteria, although we determined the cutoff value for the LDL-cholesterol level based on the results of our multicenter study 4) . Considering that FH by itself is a very high-risk condition for CAD and that untreated patients are likely to develop CAD, such as myocardial infarction and angina pectoris, at a young age 3) , providing an early diagnosis and appropriate treatment is mandatory for preventing premature death. Additionally, heterozygous FH is detected in one in 137 to 500 individuals and is one of the most frequently encountered genetic • Diagnosis should be made after excluding secondary hyperlipidemia • If a patient meets two or three of the above-mentioned criteria, the condition should be diagnosed as FH. In the case of suspected FH, diagnosis by genetic testing is desirable.
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• Xanthoma palpebrarum is not included in xanthoma tuberosum.
• Achilles tendon hypertrophy is diagnosed if the Achilles tendon thickness is ≥ 9 mm on soft X-ray imaging.
• An LDL-C of ≥ 250 mg/dL strongly suggests FH.
• If a patient is already receiving drug therapy, the lipid level that led to treatment should be used as the reference for diagnosis.
• Premature CAD is defined as CAD in men aged ＜55 years or women aged ＜65 years.
• If FH is diagnosed, it is preferable to also examine the patient's family members.
Grades of Recommendation A = can be trusted to guide practice. B = can be trusted to guide practice in most situations. C = can be used to guide practice, but care should be taken in application.
Summary of Recommendations
1. Detection of Index Cases: Screening and Phenotypic Diagnosis 1.1 Targeted, opportunistic and universal screening strategies should be employed to detect index cases [2B].
1.2 Index cases should be sought by targeted screening of adults with premature cardiovascular disease (CVD), primarily coronary heart disease (CHD) and a personal and/or family history of hypercholesterolaemia.
[1A]
1.3 Opportunistic screening of adults and children in primary care, based on age-and gender-specific plasma LDL-cholesterol levels, should be routinely adopted.
[2B]
1.4 Universal screening based on age-and gender-specific plasma LDL-cholesterol levels should be considered prior to age 20 years and ideally before puberty.
[2C]
1.5 In adults, country-specific clinical tools, such as the Dutch Lipid Clinic Network, Simon Broome, MED-PED or Japanese FH criteria, may be used to make a phenotypic diagnosis.
Endorsement
The recommendations contained in this document have been fully endorsed by The National Lipid Association, 6816 Southpoint Parkway (Suite 1000), Jacksonville, FL3316, US.
Conversion Factor
mg/dL cholesterol=mmol/L×38.7
Levels of Evidence and Grades of Recommendation
Levels of Evidence 1 = systematic review/meta-analysis/at least one randomised control trial/good quality diagnostic tests.
2 = good quality clinical or observational studies. 3 = expert opinion or clinical experience/argument from first principles.
(The evidence for therapeutic interventions was considered principally in respect of effects on plasma LDL-cholesterol concentrations, but where available was also based on data on subclinical atherosclerosis or cardiovascular outcomes.)
This executive summary has been reproduced with the permission obtained from Watts G. Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL) cholesterol and causes premature coronary heart disease. There are at least 20 million people with FH worldwide, but the majority remains undetected and current treatment is often suboptimal. To address this major gap in coronary prevention we present, from an international perspective, consensus-based guidance on the care of FH. The guidance was generated from seminars and workshops held at an international symposium. The recommendations focus on the detection, diagnosis, assessment and management of FH in adults and children, and set guidelines for clinical purposes. They also refer to best practice for cascade screening and risk notifying and testing families for FH, including use of genetic testing. Guidance on treatment is based on risk stratification, management of noncholesterol risk factors and safe and effective use of LDL lowering therapies. Recommendations are given on lipoprotein apheresis. The use of emerging therapies for FH is also foreshadowed. This international guidance acknowledges evidence gaps, but aims to make the best use of contemporary practice and technology to achieve the best outcomes for the care of FH. It should accordingly be employed to inform clinical judgment and be adjusted for country-specific and local healthcare needs and resources. 4.2 Relatives should only be directly notified of their risk without consent of the index case if there is specific legislative provision for breach of confidentiality in the relevant jurisdiction. [3C] 4.3 A proactive approach that respects the principles of privacy, justice and autonomy is required.
[3A]
4.4 Pre-testing counselling should be offered to at risk family members of an index case prior to any form of testing. [1A] 4.5 Systematic cascade screening should ideally be co-ordinated by a dedicated centre and should not be carried out in primary care without central co-ordination, particularly if employing DNA testing. [1B] 4.6 Cascade screening of families should be carried out using both a phenotypic and genotypic strategy, but if DNA testing is not available a phenotypic strategy alone should be used [1A] 4.7 Cascade screening should initially be carried out as a priority in first-degree relatives and then extended to second-and third-degree relatives. [1A] 4.8 In the absence of genetic testing, the diagno- 6.5 Plasma levels of hepatic aminotransferases, creatine kinase, glucose and creatinine should be measured before starting drug therapy. All patients on statins should have hepatic aminotransferases monitored; creatine kinase should be measured when musculoskeletal symptoms are reported; glucose should be monitored when there are risk factors for diabetes.
[2A]
6.6 All women of child-bearing age should receive pre-pregnancy counselling, with appropriate advice on contraception, before starting a statin and this should be reinforced at annual review. [2A] 6.7 Statins and other systemically absorbed lipid regulating drugs should be discontinued 3 months before planned conception, as well as during pregnancy and breast feeding. [2A] 6.8 Although carotid ultrasonography has been used in clinical trials, its role in monitoring therapy as part of the clinical care for FH has not been established and it should therefore not be used at present for this purpose. [3C] 6.9 Lomitapide and Mipomersen should be considered as adjunctive treatments to diet and cholesterol lowering drugs in adults with homozygous FH to further reduce plasma LDL-cholesterol, particularly if lipoprotein apheresis is not available. [1C] 6.10 Well controlled and low complexity patients should be followed-up in primary care, whereas higher complexity patients will need regular review by a specialist, with the option of shared care. Review intervals should vary according to clinical context. Opportunities should be created for integrating the primary and specialist care of FH.
[3B]
Management of Children and Adolescents
7.1 Patients must receive advice on lifestyle modifications and on correcting non-cholesterol risk factors; primordial prevention (counselling to inhibit the development of risk factors) is particularly important.
7.2 To lower elevated plasma LDL-cholesterol in this age group generally requires a fat-modified, hearthealthy diet and a statin, with the possible addition of ezetimibe or a bile acid sequestrant. [1A] 7.3 All patients should be treated with diet, with statins considered at age 8 to 10 years and ideally started before age of 18 years; plasma LDL-cholesterol targets in this age group need not be as intense as for sis of FH should be made in close relatives using age-, gender-and country-specific plasma LDL-cholesterol levels. Diagnostic clinical tools for index cases, such as the Dutch Lipid Clinic Network and Simon Broome criteria, should not be employed to make the diagnosis of FH in relatives [1A] 4.9 DNA testing makes cascade screening more cost-effective and should be employed to screen family members after the mutation is identified in the index case. [1A] 4.10 Children with xanthomata or other physical findings of homozygous FH, or at risk of homozygous FH should be screened as early as possible and definitely by 2 years of age. [2A] 4.11 Children with suspected heterozygous FH should be screened between the ages of 5 and 10 years; age at screening should be similar in boys and girls.
Genetic Testing 5.1 Genetic testing for FH should ideally be offered to all 'index cases' who have a phenotypic diagnosis of FH. [3A]
5.2 When the phenotypic diagnosis of FH is unlikely (e.g. by Dutch Lipid Clinic Network Criteria), genetic testing of the 'index case' need not be carried out. [1C] 5.3 Genetic testing for FH must be carried out in an accredited laboratory using standardised methods that target specific mutations and/or by exon-byexon sequencing. [1A] 5.4 If genetic testing detects a variant, its significance as a pathogenic mutation, a previously reported variant of uncertain significance, a novel variant of uncertain significance or a benign (normal) variant needs to be assessed and recorded. [1A] 5. 6.2 Therapy should ideally aim for at least a 50% reduction in plasma LDL-cholesterol, followed by an LDL-cholesterol ＜2.5 mmol/L (absence of CHD or other major risk factors) and ＜1.8 mmol/L (presence of CHD or other major risk factors). [2C] 6.3 Achieving these targets will require a fatmodified, heart-healthy diet and statin therapy with 7.8 Although statins can be safely used in children, weight, growth, physical and sexual development, and well-being should be monitored in this age group. [1A] 7.9 Plasma levels of hepatic aminotransferases, creatine kinase, glucose and creatinine should be measured before starting drug therapy. All patients on statins should have hepatic aminotransferases monitored; creatine kinase should be measured and compared to pre-treatment levels when musculoskeletal symptoms are reported; glucose should be monitored if there are risk factors for diabetes. [2A] 7.10 All adolescent girls should receive pre-pregnancy counselling, with appropriate advice on contraception, before starting a statin and this should be reinforced at annual review. [3A] .
7.11 Although carotid ultrasonography has been used in clinical trials, its role in monitoring therapy in patients with heterozygous FH has not been established and it should therefore not be used for this purpose. [3C] 7.12 Well controlled and lower complexity patients should be followed up in primary care, whereas higher complexity patients will need regular review by a paediatrician. Opportunities should be created for integrated care between GPs and paediatricians. Family based and transitional care clinics should be considered by adult and paediatric services. [3B] 7.13 Children with homozygous FH should be referred on diagnosis to a specialist centre and drug and/or apheresis treatment commenced as soon as
